ATTENTION NASDAQ: MREO INVESTORS: Contact Berger Montague About a Mereo BioPharma Group PLC Class Action Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc on behalf of investors who purchased Mereo American Depositary Shares during the specified Class Period, alleging misleading information regarding clinical study results [1][3]. Company Overview - Mereo BioPharma Group plc is a biopharmaceutical company headquartered in London, focusing on treatments for rare diseases [2]. Legal Action Details - The lawsuit claims that Mereo misled investors by raising expectations about the ORBIT and COSMIC studies for setrusumab, which did not significantly reduce clinical fracture rates compared to control groups [3]. - Following the disclosure of the study results, Mereo's ADS price fell dramatically from $2.31 on December 26, 2025, to $0.29 on December 29, 2025, resulting in a loss of over 87.7% of its value in one day [3]. Investor Information - Investors who purchased Mereo securities during the Class Period have until April 6, 2026, to seek appointment as a lead plaintiff representative of the class [2].